Nucleoside reverse transcriptase inhibitor backbones and pregnancy outcomes

被引：17

作者：

Bailey, Heather ^{[1
]}

Goetghebuer, Tessa ^{[2
]}

Gingaras, Cosmina ^{[3
]}

Grawe, Claudia ^{[4
]}

Tomas Ramos, Jose ^{[5
]}

Thorne, Claire ^{[1
]}

Favarato, Graziella ^{[6
]}

Malyuta, Ruslan ^{[6
]}

Volokha, Alla ^{[6
]}

Rozenberg, Vladimir

Voronin, Evgeny

Plotnikova, Yulia

Prieto, Luis ^{[7
]}

Mendoza, Natalia

Fortuny, Claudia

Garcia, Lourdes

de Tejada, Begona Martinez ^{[8
]}

Aebi-Popp, Karoline ^{[8
]}

Peters, Helen ^{[9
]}

Sconza, Rebecca ^{[9
]}

Barlow, P. ^{[6
]}

Manigart, Y. ^{[6
]}

Gilles, C. ^{[6
]}

Hainaut, M. ^{[6
]}

Goetghebuer, T. ^{[6
]}

Brichard ^{[6
]}

Van der Linden, D. ^{[6
]}

Pilipenko, T. ^{[6
]}

Zayats, A. ^{[6
]}

Posokhova, S. ^{[6
]}

Kaleeva, T. ^{[6
]}

Barishnikova, Y. ^{[6
]}

Servetsky, S. ^{[6
]}

Teretsenko, R. ^{[6
]}

Stelmah, A. ^{[6
]}

Kiseleva, G. ^{[6
]}

Dotsenko, E. ^{[6
]}

Zalata, O. A. ^{[6
]}

Solokha, S. ^{[6
]}

Grazhdanov, M. P. ^{[6
]}

Kulakovskaya, E. ^{[6
]}

Bashkatova, N. ^{[6
]}

Gigil, V ^{[6
]}

Raus, I ^{[6
]}

Yurchenko, O., V ^{[6
]}

Adeyanova, I ^{[6
]}

Ruban, Z. ^{[6
]}

Govorun, O. ^{[6
]}

Ostrovskaya, O. ^{[6
]}

Kochergina, I ^{[6
]}

机构：

[1] Inst Child Hlth, Great Ormond St, London, England

[2] CHU St Pierre, European Collaborat Study, Brussels, Belgium

[3] Victor Babes Hosp Cohort, Bucharest, Romania

[4] Univ Zurich, Swiss Mother & Child HIV Cohort Study, Zurich, Switzerland

[5] Hosp Clin Madrid, Pediat Dept, Madrid Cohort HIV Infected Mother Infant Pairs, Madrid, Spain

[6] European Collaborat Study, Kiev, Ukraine

[7] Madrid Cohort HIV Infected Mother Infant Pairs, Madrid, Spain

[8] Swiss Mother & Child HIV Cohort Study, Zurich, Switzerland

[9] UK & Ireland Natl Study HIV Pregnancy & Childhood, London, England

来源：

AIDS | 2019年 / 33卷 / 02期

关键词：

antiretroviral therapy; Europe; HIV; nucleoside reverse transcriptase inhibitor backbones; pregnancy; preterm delivery; small-for-gestational age; TO-CHILD TRANSMISSION; ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED WOMEN; PRETERM DELIVERY; BIRTH OUTCOMES; RISK; PREVENTION; PROTEASE; INTERGROWTH-21ST;

D O I：

10.1097/QAD.0000000000002039

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Objectives: The aim of this study was to investigate whether specific nucleoside reverse transcriptase inhibitor (NRTI) backbones are associated with risk of adverse pregnancy outcomes among pregnant women starting antiretroviral therapy (ART). Design: Seven observational studies across eight European countries of pregnancies in HIV-positive women. Methods: Individual-level data were pooled on singleton pregnancies conceived off-ART in which a single combination ART regimen was initiated at least 2 weeks before delivery, and ending in a live birth in 2008-2014. Preterm delivery (PTD) was defined as less than 37 gestational weeks and small-for-gestational-age (SGA) as less than 10th percentile according to INTERGROWTH standards. Poisson regression models were fitted to investigate associations between NRTI backbones and PTD/SGA. Results: Out of 7193 pregnancies, 45% (3207) were in UK/Ireland, 44% (3134) in Ukraine. 10% (722/7193) of deliveries were preterm and 11.1% (785/7089) of newborns SGA. The most common NRTI backbones were zidovudine (ZDV)-lamivudine (3TC) (71%), tenofovir (TDF)-XTC (16%) and abacavir (ABC)-3TC (10%) with TDF-containing backbone use increasing over time. Overall, 77% of regimens contained ritonavir-boosted lopinavir (LPV/r). There was no association between NRTI backbone and PTD in main adjusted analyses [adjusted prevalence ratios (aPRs) 0.97 (95% confidence interval, 95% CI 0.73-1.28] for ABC-3TC and aPR 1.06 (95% CI 0.831.35) for TDF-XTC, both vs. ZDV-3TC) or in 4720 pregnancies on LPV/r [aPR 1.03 (95% CI 0.74-1.43) for ABC-3TC and aPR 1.16 [0.85-1.57] for TDF-XTC, both vs. ZDV-3TC]. Infants exposed to ABC-3TC or TDF-XTC in utero were less likely to be SGA than those exposed to ZDV-3TC [aPR 0.72 (95% CI 0.53-0.97) and aPR 0.70 (95% CI 0.53-0.93), respectively]. Conclusion: Results support the safety of TDF-XTC backbones initiated in pregnancy with respect to gestation length and birthweight. Copyright (C) 2018 Wolters Kluwer Health, Inc. All rights reserved.

引用

页码：295 / 304

页数：10

共 38 条

[1]

[Anonymous], 2013, CONGUID UANT DRU

[2]

[Anonymous], HIV INF UKR INF B

[3]

[Anonymous], UNAIDS EST TREATM CA

[4]

[Anonymous], INT SCI PRACT C CHIL

[5]

[Anonymous], UNAIDS EST COV PREGN

[6]

[Anonymous], 19 ANN NAT HIV NURS

[7] Pregnancy outcomes in HIV-positive women in Ukraine, 2000-12 (European Collaborative Study in EuroCoord): an observational cohort study [J].

Bagkeris, Emmanouil ;

Malyuta, Ruslan ;

Volokha, Alla ;

Cortina-Borja, Mario ;

Bailey, Heather ;

Townsend, Claire L. ;

Thorne, Claire .

LANCET HIV, 2015, 2 (09) :E385-E392

[8] Syphilis, hepatitis C and HIV in Eastern Europe [J].

Bailey, Heather ;

Turkova, Anna ;

Thorne, Claire .

CURRENT OPINION IN INFECTIOUS DISEASES, 2017, 30 (01) :93-100

[9] Pregnancy plus - Pregnancy and injecting drug use [J].

Bell, James ;

Harvey-Dodds, Lucy .

BMJ-BRITISH MEDICAL JOURNAL, 2008, 336 (7656) :1303-1305

[10] Highly Active Antiretroviral Therapy and Adverse Birth Outcomes Among HIV-Infected Women in Botswana [J].

Chen, Jennifer Y. ;

Ribaudo, Heather J. ;

Souda, Sajini ;

Parekh, Natasha ;

Ogwu, Anthony ;

Lockman, Shahin ;

Powis, Kathleen ;

Dryden-Peterson, Scott ;

Creek, Tracy ;

Jimbo, William ;

Madidimalo, Tebogo ;

Makhema, Joseph ;

Essex, Max ;

Shapiro, Roger L. .

JOURNAL OF INFECTIOUS DISEASES, 2012, 206 (11) :1695-1705

← 1 2 3 4 →